Compare CTNM & ANSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CTNM | ANSC |
|---|---|---|
| Founded | 2009 | 2021 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.5M | 469.1M |
| IPO Year | 2024 | N/A |
| Metric | CTNM | ANSC |
|---|---|---|
| Price | $13.47 | $11.33 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 172.1K | 115.5K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $55.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.57 | $10.70 |
| 52 Week High | $16.33 | $11.38 |
| Indicator | CTNM | ANSC |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 51.62 |
| Support Level | $11.62 | $11.01 |
| Resistance Level | $15.57 | N/A |
| Average True Range (ATR) | 0.72 | 0.01 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 41.35 | 37.50 |
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Agriculture & Natural Solutions Acquisition Corp is a blank check company.